Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology

HAMILTON, Bermuda, April 17, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present clinical and preclinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ), at the 77^th Annual Meeting of the Society for Investigative Dermatology (SID) at the Chicago Hilton in Chicago, IL.

“The results being presented at SID provide further scientific rationale for targeting OSMRβ and dual pathway inhibition of IL-31 and OSM via KPL-716 for the potential treatment of chronic pruritic diseases,” said Dr. John F. Paolini, MD, PhD, FACC, Chief Medical Officer at Kiniksa.

Presentations include:

KPL-716, Anti-OSMRβ Antibody, Reduced Pruritus in Atopic Dermatitis

• Oral Presentation: Concurrent Mini-Symposium #4 on Thursday, May 9^th, 2019 from 1:30 p.m. to 4:00 p.m. Central Time in International Ballroom South
• Poster Presentation: Poster Session III (#560) on Saturday, May 11^th, 2019 from 12:45 p.m. to 2:45 p.m. Central Time in Stevens Salons B/C/D
• Lead Author: Zamaneh Mikhak, Kiniksa Pharmaceuticals Corp., Lexington, Massachusetts, USA

OSM Induction of Monocyte Chemoattractant Protein 1 (MCP-1) in Human Epidermal Keratinocytes is Inhibited by Anti-OSMRβ Monoclonal Antibody KPL-716

• Poster Presentation: Poster Session I (#637) on Thursday, May 9^th, 2019 from 10:45 a.m. to 12:45 p.m. Central Time in Stevens Salons B/C/D
• E-Poster Presentation: E-Poster Discussions II on Friday, May 10^th, 2019 from 10:45 a.m. to 11:45 a.m. Central Time in Continental Ballroom C
• Lead Author: Carl D. Richards, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada

The OSMRβ Axis Identified in Prurigo Nodularis

• Poster Presentation: Poster Session I (#202) on Thursday, May 9^th, 2019 from 10:45 a.m. to 12:45 p.m. Central Time in Stevens Salons B/C/D
• Lead Author: Zamaneh Mikhak, Kiniksa Pharmaceuticals Corp., Lexington, Massachusetts, USA

KPL-716, an OSMRβ Monoclonal Antibody, Reduces IL-31-Induced Scratching Behavior in Cynomolgus Monkeys: Establishment and Optimization of Pharmacokinetic/Pharmacodynamic Model

• Poster Presentation: Poster Session II (#1002) on Friday, May 10^th, 2019 from 11:15 a.m. to 1:15 p.m. Central Time in Stevens Salons B/C/D
• Lead Author: Rohan Gandhi, Kiniksa Pharmaceuticals Corp., Lexington, Massachusetts, USA

Kiniksa intends to make the abstracts available through the Investors and Media section of its website (www.kiniksa.com) upon their publication in the Journal of Investigative Dermatology (JID) on Friday, April 19^th, 2019.

About KPL-716
KPL-716 is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of IL-31 and OSM, two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes KPL-716 to be the only monoclonal antibody in development that targets both pathways simultaneously.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.

Every Second Counts!™

Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com